BioCentury | Feb 6, 2021
Politics, Policy & Law

Biotech isn’t tech; M&A isn’t all the same

...that started out in the labs of Organon, which was looking for autoimmune disease treatments. Organon...
...financial resources into developing Keytruda at a speed and with an intensity that Schering and Organon...
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...Matthew Walsh as CFO and Rachel Stahler as chief information officer of its planned spinout Organon...
...to complete the spin out of its women’s health business, legacy brands and biosimilars into Organon...
BioCentury | Mar 10, 2014
Finance

The thesis on Thesan

...and CSO of pain company Kadmus Pharmaceuticals Inc. , which sold its key assets to Organon BioSciences N.V....
BioCentury | Sep 30, 2013
Clinical News

Bridion sugammadex regulatory update

...its 2009 acquisition of Schering-Plough Corp. Schering-Plough gained the compound through its 2007 acquisition of Organon BioSciences N.V....
BioCentury | Jul 22, 2013
Clinical News

Bridion sugammadex regulatory update

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon BioSciences N.V....
BioCentury | May 13, 2013
Clinical News

Bridion sugammadex regulatory update

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon BioSciences N.V....
BioCentury | Apr 15, 2013
Company News

Incyte Pharmaceuticals Inc., NV Organon deal

...sequence and expression database and LifeSeq GeneAlbum reagent set in exchange for annual access fees. Organon...
...collaboration. INCY is eligible to receive royalties. Incyte Pharmaceuticals Inc. (INCY), Palo Alto, Calif. NV Organon...
BioCentury | Dec 20, 2012
Strategy

MRC Technology extends reach

...for milestones and royalties. Organon has all rights to develop and commercialize the humanized antibody. Organon...
BioCentury | Nov 5, 2012
Clinical News

Bridion sugammadex: Phase III completed

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon BioSciences N.V....
BioCentury | Apr 18, 2011
Company News

Merck pharmaceuticals news

...Merck's Organon N.V. subsidiary proposed to restructure and reduce headcount of R&D at Dutch sites Oss...
...reduce headcount of R&D at Dutch sites Oss and Schaijk by 551 (53%) to 479. Organon...
Items per page:
1 - 10 of 362
BioCentury | Feb 6, 2021
Politics, Policy & Law

Biotech isn’t tech; M&A isn’t all the same

...that started out in the labs of Organon, which was looking for autoimmune disease treatments. Organon...
...financial resources into developing Keytruda at a speed and with an intensity that Schering and Organon...
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...Matthew Walsh as CFO and Rachel Stahler as chief information officer of its planned spinout Organon...
...to complete the spin out of its women’s health business, legacy brands and biosimilars into Organon...
BioCentury | Mar 10, 2014
Finance

The thesis on Thesan

...and CSO of pain company Kadmus Pharmaceuticals Inc. , which sold its key assets to Organon BioSciences N.V....
BioCentury | Sep 30, 2013
Clinical News

Bridion sugammadex regulatory update

...its 2009 acquisition of Schering-Plough Corp. Schering-Plough gained the compound through its 2007 acquisition of Organon BioSciences N.V....
BioCentury | Jul 22, 2013
Clinical News

Bridion sugammadex regulatory update

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon BioSciences N.V....
BioCentury | May 13, 2013
Clinical News

Bridion sugammadex regulatory update

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon BioSciences N.V....
BioCentury | Apr 15, 2013
Company News

Incyte Pharmaceuticals Inc., NV Organon deal

...sequence and expression database and LifeSeq GeneAlbum reagent set in exchange for annual access fees. Organon...
...collaboration. INCY is eligible to receive royalties. Incyte Pharmaceuticals Inc. (INCY), Palo Alto, Calif. NV Organon...
BioCentury | Dec 20, 2012
Strategy

MRC Technology extends reach

...for milestones and royalties. Organon has all rights to develop and commercialize the humanized antibody. Organon...
BioCentury | Nov 5, 2012
Clinical News

Bridion sugammadex: Phase III completed

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon BioSciences N.V....
BioCentury | Apr 18, 2011
Company News

Merck pharmaceuticals news

...Merck's Organon N.V. subsidiary proposed to restructure and reduce headcount of R&D at Dutch sites Oss...
...reduce headcount of R&D at Dutch sites Oss and Schaijk by 551 (53%) to 479. Organon...
Items per page:
1 - 10 of 362